Pomalidomide Capsules Suppliers & Bulk Manufacturers
Available Forms: capsules.
Available Strengths: 2 mg, 4 mg, 3 mg, and 4 mg
Reference Brands: Talquetamide(US), Pomalyst(EU)
Category:
Orphan Drugs
Pomalidomide is an immunomodulatory drug that enhances immune response and inhibits tumor growth by modulating cytokine production and stimulating T-cell activity. It effectively treats refractory multiple myeloma, improving survival, decreasing tumor burden, and supporting long-term disease control while supporting immune health.
Pomalidomide Capsules is available in capsules.
and strengths such as 2 mg, 4 mg, 3 mg, and 4 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pomalidomide Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pomalidomide Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pomalidomide capsules, marketed as Pomalyst, are approved in the US by the FDA and in the EU via EMA for relapsed and refractory multiple myeloma. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data to ensure safety and effectiveness, while the EMA evaluates compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional requirements supports timely approval, safe use, and widespread availability, helping improve long-term outcomes for multiple myeloma patients worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing